The National Research Development Corporation (NRDC), an enterprise of the Department of Scientific & Industrial Research, and Chaturbhuj Pharmaceutical Co, Haridwar have entered into license agreement for commercialisation of Ayush-82, an ayurvedic formulation for management of diabetes.

NRDC chairman and managing director Dr H Purushotham said that Ayush-82 was developed by Central Council for Research in Ayurvedic Sciences (CCRAS), an autonomous organisation under the Ministry of Ayush. The licence agreement was signed by Dr. Purushotham, on behalf of NRDC, and Murari Sharma, proprietor, Chaturbhuj Pharmaceutical Co, Haridwar. NRDC has so far licensed 13 ayurvedic technologies developed by CCRAS to more than 33 companies in India

Ayush-82; an anti diabetic drug developed by CCRAS is a combination of known and tested hypoglycemic drugs. Its clinical studies have been done extensively. Diabetes mellitus is a group of metabolic diseases marked by high level of blood glucose resulting from defects in insulin production, insulin action or both. Diabetes may lead to serious complications in multiple organ systems. The use of this cost effective drug would help millions of people suffering from diabetes.

Besides, the NRDC has entered into a memorandum of agreement (MoA) with the Centre for Nano and Material Sciences (CNMS) of Jain University, Karnataka for commercialisation of technologies/intellectual properties developed at CNMS. NRDC shall also provide its services in IP evaluation/valuation in terms of their commercial potential.

Chairman and managing director, NRDC Dr H Purushotham, and director CNMS, Jain University Dr Geetha Balakrishna, have signed MoA for IP protection and technology commercialisation of their scientific and technological developments. The MoA is valid for a period of 10 years from May, 2016.